Foscenvivint

Phase 2Small molecule

KKiminori Kimura, MD

Foscenvivint is one of 20 small molecule programs targeting Liver Cirrhosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver CirrhosisRecruiting

HemophiliaActive, not recruiting

Liver CirrhosisPhase 2

Recruiting

HemophiliaPhase 2

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Hemophilia

#DrugCompanyPhaseTrials

Hemlibra

Roche

Approved

3 2

Videx

Bristol-Myers Squibb

Approved

1 3

Epivir

GGlaxo Dba Glaxosmithkline

Approved

1 4

Zerit

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 5

Hivid

CConrado Roberto Hoffmann Filho

Approved

1 6

Cyklokapron

JJ Molner

Approved

—7

Crixivan

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

1 8

Qfitlia

GGenzyme, a Sanofi Company

Approved

4 9

Antithrombin Concentrate (ATIIIC)

Sanofi

Phase 3

3 10

Foscenvivint

KKiminori Kimura, MD

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Liver Cirrhosis

NCT07681089

Clinical

Trials by Indication[1]

Hemophilia1 trial

A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection with Hemophilia (OP-724-H201)

Active, not recruiting·KKiminori Kimura, MD·Phase 2·NCT06144086·6 enrolled

Liver Cirrhosis1 trial

A Multicenter, Single-Arm, Open-Label Phase 2 Study of Once-Weekly Foscenvivint in Patients With Liver Cirrhosis Due to HIV/HCV Co-infection in the Setting of Hemophilia

Recruiting·KKiminori Kimura, MD·Phase 2·NCT07681089·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Foscenvivint. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Foscenvivint compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Foscenvivint. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kiminori Kimura, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKiminori Kimura, MD

Foscenvivint

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Hemophilia1 trial

Liver Cirrhosis1 trial

References

Drug Info

Quick Facts

Related News